The stock of Asta Funding, Inc. (NASDAQ:ASFI) hit a new 52-week high and has $12.04 target or 7.00% above today’s $11.25 share price. The 8 months bullish chart indicates low risk for the $74.52 million company. The 1-year high was reported on Feb, 11 by Barchart.com. If the $12.04 price target is reached, the company will be worth $5.22 million more. The stock increased 3.21% or $0.35 during the last trading session, reaching $11.25. About 209,616 shares traded or 1155.71% up from the average. Asta Funding, Inc. (NASDAQ:ASFI) has declined 32.37% since February 11, 2017 and is downtrending. It has underperformed by 49.07% the S&P500.
Sunesis Pharmaceuticals Incorporated (NASDAQ:SNSS) had an increase of 7.43% in short interest. SNSS’s SI was 453,900 shares in February as released by FINRA. Its up 7.43% from 422,500 shares previously. With 89,400 avg volume, 5 days are for Sunesis Pharmaceuticals Incorporated (NASDAQ:SNSS)’s short sellers to cover SNSS’s short positions. The SI to Sunesis Pharmaceuticals Incorporated’s float is 3.73%. The stock decreased 3.14% or $0.18 during the last trading session, reaching $5.55. About 118,063 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since February 11, 2017 and is uptrending. It has underperformed by 8.37% the S&P500.
Asta Funding, Inc., together with its subsidiaries, engages in the consumer receivable business in the United States. The company has market cap of $74.52 million. The firm operates through four divisions: Consumer Receivables, Personal Injury Claims, Structured Settlements, and GAR Disability Advocacy. It currently has negative earnings. The Consumer Receivables segment involved in the purchase, management, and servicing distressed consumer receivables, including charged-off receivables consisting of accounts that have been written-off by the originators and might have been previously serviced by collection agencies; semi-performing receivables, including accounts where the debtor is currently making partial or irregular monthly payments, but the accounts might have been written-off by the originators; and performing receivables comprising accounts where the debtor is making regular monthly payments that might or might not have been delinquent in the past.
Investors sentiment decreased to 0.83 in Q3 2017. Its down 0.03, from 0.86 in 2017Q2. It is negative, as 3 investors sold Asta Funding, Inc. shares while 3 reduced holdings. 2 funds opened positions while 3 raised stakes. 1.10 million shares or 2.56% less from 1.13 million shares in 2017Q2 were reported. Royal Bancorp Of Canada stated it has 7,104 shares. Blackrock Inc reported 286,237 shares. Bridgeway Mngmt Inc holds 122,100 shares or 0.01% of its portfolio. Nationwide Fund has 267 shares for 0% of their portfolio. Geode Capital Management Ltd Liability Corp stated it has 0% in Asta Funding, Inc. (NASDAQ:ASFI). Northern Tru Corporation owns 14,466 shares. Envestnet Asset Mgmt Inc holds 0% of its portfolio in Asta Funding, Inc. (NASDAQ:ASFI) for 53 shares. Rbf Limited stated it has 400,000 shares. Dimensional Fund L P holds 91,775 shares. Manufacturers Life Insurance Co The has 0% invested in Asta Funding, Inc. (NASDAQ:ASFI) for 1,067 shares. Bank Of America Corporation De holds 0% or 10 shares in its portfolio. Vanguard Gp reported 0% in Asta Funding, Inc. (NASDAQ:ASFI).
Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Sunesis Pharmaceuticals had 11 analyst reports since July 24, 2015 according to SRatingsIntel. On Thursday, December 14 the stock rating was initiated by Oppenheimer with “Buy”. The rating was downgraded by Cantor Fitzgerald on Friday, July 24 to “Hold”. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) earned “Buy” rating by Oppenheimer on Monday, November 20. The company was downgraded on Friday, July 24 by TH Capital. The company was downgraded on Tuesday, December 5 by Wells Fargo. The rating was downgraded by Cowen & Co to “Market Perform” on Friday, July 24. The firm earned “Hold” rating on Thursday, July 27 by Cantor Fitzgerald. The firm earned “Buy” rating on Monday, December 11 by Wells Fargo. Cantor Fitzgerald maintained the shares of SNSS in report on Tuesday, July 18 with “Hold” rating. Wells Fargo upgraded the stock to “Outperform” rating in Friday, July 29 report.